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Abstract – Serotonin is regarded as one of the most important factors in modern psychiatry and a significant 
amount of research is associated with that neurotransmitter in some way. Serotonin transporter and its vari-
ous polymorphisms are implied to be connected with various psychiatric disorders, mostly depression and 
suicide. In light of that fact, this review article will try to address new and current data regarding serotonin 
transporter polymorphisms and their association with depression. As this area of research in psychiatry is 
constantly growing and nowadays incorporates various other factors than was the case previously it was 
necessary to provide a brief overview of those factors. Therefore, data regarding serotonin transporter poly-
morphisms and its relation with gene-environment interactions, biological stress reactivity and personality 
traits and their possible combined effects on depression are discussed. No matter how big is the quantum of 
knowledge and research regarding serotonin, the only constant finding when analyzing the possible associa-
tion of serotonin transporter polymorphism and depression are inconsistent conclusions. Therefore it can be 
concluded that molecular and neural mechanisms that underlie the interplay of genes, environmental adver-
sity and personality traits that constitute disease risk remain incompletely understood. Due to these incon-
sistent conclusions, further genotyping of SLC6A4 and other genes is necessary, as well as studies performed 
on bigger samples of participants. Factors like life stress and environmental factors, which may contribute 
to increased vulnerability in susceptible individuals, should also be more extensively addressed as they may 
prove be the key to timely treatment and effective preventive strategies.
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Introduction
Much has been written about serotonin, 
its physiology and effects through the 
course of  time but we still cannot claim to 
know everything about this neurotransmit-
ter. Serotonin is regarded as one of  the most 
important factors in modern psychiatry and 
therefore is no wonder that many studies 
deal with serotonin in one way or another. 
Research regarding serotonin transporter is 
no exception and this article will try to pro-
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vide a closer and more concise report of  re-
search conducted thus far.
5-hydroxytryptamine, or just serotonin, 
plays an important role in neurodevelop-
ment and functioning of  the brain. It is 
involved in regulation of  a wide variety of  
functions and behaviors such as appetite, 
sleep, mood, motor activity, emotions and 
altered neuroendocrine function [1]. Sero-
tonin functions as a short-range neurotrans-
mitter, a paracrine neuronal modulator at 
a number of  different receptors and as a 
long-range signaling modulator. Its effects 
are multiple and spread throughout the or-
ganism via plasma, platelet, neuroendocrine, 
gut, adrenal and other peripheral systems 
across many species [2].
The serotonin transporter (5-HTT) is 
a monoamine transporter protein with a 
crucial role in serotoninergic function.  It 
terminates synaptic actions of  5-HT and 
transports it from synaptic spaces into pre-
synaptic neurons, effectively recycling it 
into the neurotransmitter pool [3]. 5-HTT 
also has a major role in regulation of  the 
homeostasis of  spatial distribution and in-
tensity of  5-HT signals with 5-HT recep-
tors [4-6]. Serotonin transporter is encoded 
by the gene termed SLC6A4 that maps to 
chromosome 17q11.2. It is composed of  15 
exons spanning about 40 kb. The sequence 
of  the transcript predicts a protein com-
prised of  630 amino acids with 12 trans-
membrane domains. Alternative promoters, 
differential splicing involving exons 1A, B, 
and C, and 30-untranslated-region variabil-
ity result in multiple mRNA species, as well 
as specific polymorphisms, that are likely 
to regulate gene expression SLC6A4 in hu-
mans. Best studied is the promoter region 
polymorphism, 5-HTTLPR, which together 
with two intrinsic single nucleotide poly-
morphisms (SNP’s) [rs25531 and rs25532], 
all located upstream of  the transcription 
start site, modulate the transcriptional activ-
ity of  SLC6A4 [2,7-9]. Additional variants 
at the SLC6A4 locus include a functional 
variable number of  tandem repeats (VNTR) 
polymorphism in intron 2 and a number 
of  other coding region SNP’s that change 
the structure or function of  the transporter 
protein, such as I425V and G56A [2,8,10-
13]. Most of  these SNP’s are rare [7,14].
As mentioned, best studied polymor-
phisms of  the serotonin system are linked 
with the 5-HTT gene-linked polymorphic 
region (5-HTTLPR), a repetitive element of  
varying length located in the promoter re-
gion of  SLC6A4. It modulates the transcrip-
tional activity of  human 5-HTT. Alleles of  
the serotonin transporter polymorphism are 
most commonly composed of  either four-
teen (short or S allele) or sixteen (long or L 
allele) repeated elements which affect trans-
porter expression and function [15]. How-
ever, other alleles have also been identified 
at low frequency, including 15-, 18-, 19-, 20-, 
and 22-repeat alleles, with various addition-
al SNPs distinguishing some repeats [16]. 
More recently, 5-HTTLPR polymorphisms 
have been researched from a newer view-
point. Specifically, an A/G nucleotide sub-
stitution in the L allele renders the 5-HTTL-
PR tri-allelic with the functional variants of  
the L allele designated as LA and LG [17]. 
Similar was observed for the S allele and it 
was subdivided into SA and SG18. It was 
observed that the A variant - LA produces 
high levels of  mRNA and that the G variant 
- LG is equivalent to the S allele [7,19,20]. 
Other polymorphisms in this gene that 
have been reported include: functional 
VNTR polymorphism comprised of  9, 10, or 
12 copies of  a 16/17 bp element located in 
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intron 2 of  the serotonin transporter gene, 
termed Stin2 VNTR and a single nucleotide 
polymorphism (SNP)  in the 30 untranslated 
region (UTR)  [4,21-23]. 
Short and long alleles of  the 5-HTTL-
PR have different transcription rates, which 
leads to different SERT mRNA, protein lev-
els and 5-HT uptake activity [4]. The long al-
lele has been associated with a two- to three-
fold more efficient transcription of  the gene, 
compared to the short allele, which would 
be less active resulting in reduced serotonin 
uptake [18,23,24]. Consistently, Greenberg 
and associates have established that in hu-
man healthy males, the L allele is associated 
with more rapid initial platelet 5-HT uptake 
[25]. However, a study by Kaiser and associ-
ates did not replicate this observation [26]. 
Hanna and associates found that subjects 
with LL and LS genotypes exhibit signifi-
cantly higher platelet 5-HT levels than those 
with the SS genotype [27]. Several newer 
studies found that the S allele of  5-HT-
TLPR, as well as rs25531 and rs25532 SNP 
variants (and most likely the shorter STin2 
VNTR 9 and 10 repeat alleles) might cause 
50–80% lower expression levels of  SERT. 
In contrast, higher-expressing SERT alleles 
can lead to a 5-fold greater serotonin uptake 
capacity. Murphy and associates concluded 
that combinations of  the frequent SLC6A4 
variants, and possibly also the less common 
variants, may act together to confer from 
five to twenty-fold differences in SERT ex-
pression and function levels [2]. All that be-
ing said transcriptional efficiency was mea-
sured mostly in vitro, but in vivo long-term 
influence of  the two alleles of  5-HTTLPR 
polymorphism on serotonin pathways re-
mains mostly unknown [28].
Several researches established one more 
important aspect for further study of  sero-
tonin transporter polymorphism. That as-
pect is racial variations, as frequencies of  
the L and S alleles vary among races [5,7,22]. 
Williams and associates reported an L-allele 
frequency of  more than 70% in African and 
African–Americans, a frequency of  roughly 
50% in Europeans and a 30% or lower L-al-
lele frequency in the Japanese population [1]. 
Because the 5-HTTLPR is a functional poly-
morphism these differences might result in 
different baseline levels of  relevant measure-
ments in the serotonergic system, and differ-
ent strengths of  the association between this 
polymorphism and mental illnesses in vari-
ous ethnic groups [33].
In order to examine the effects of  sero-
tonin transporter reduction and deficiency, 
experimental models on mice have shown 
that the SERT-deficient state results in fail-
ure to re-accumulate released serotonin and 
in turn leads to decrease of  serotonin brain-
tissue concentrations by 40-60% [29-31]. In 
these mice blood plasma and platelets are 
devoid of  serotonin and most peripheral or-
gans have markedly depleted serotonin lev-
els [29,31]. However, SERT reduced mice do 
not express similar traits. Therefore, the loss 
of  one SLC6A4 allele leads to a decrease in 
many transporter functions, but this single 
copy of  a SLC6A4 allele is adequate to main-
tain most overall tissue serotonin homeosta-
sis [2].
As far as the VNTR region is concerned, 
it has been suggested that it may act as a tran-
scriptional regulator of  the serotonin trans-
porter gene in allele-dependent manner, with 
12 repeat allele having stronger enhancer-like 
properties than 10 repeat allele [32]. Also, it 
has been noted that individuals homozygous 
for the 12-repeat allele had lower affinity of  
5-HT uptake than individuals who had the 
10/9 genotype [16].
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Serotonin Transporter Polymorphism 
and its Association with Psychiatric 
Disorders
There is a vast amount of  evidence sup-
porting the association between the sero-
tonin transporter polymorphism and various 
psychiatric disorders and phenotypes. S allele 
was shown to be associated with a variety of  
emotional disorders and psychopathological 
traits such as the following: depression [34], 
suicidality [33,35], bipolar affective disorder 
[36,37], schizophrenia [38], anxiety disorders 
[22,39-41], post-traumatic stress disorder 
[42], panic disorder [43,44], panic disorder 
comorbid with bipolar disorder [45], obses-
sive-compulsive disorder [46], eating disor-
ders, impulsivity–aggression, certain types of  
alcoholism, autism and Alzheimer’s disease 
[28,47].
All that being said, reports on the asso-
ciation of  the 5-HTTLPR with mental dis-
orders have produced inconsistent findings. 
Several studies report lack of  association of  
the S allele or the SS genotype to most of  
the aforementioned conditions [48-51]. Ac-
cording to the research of  Veletza and associ-
ates, some reports even claim that the L allele 
and the LL genotype constitute risk factors 
for certain conditions including adolescent 
hyperkinetic disorder, adolescent violence, 
obsessive–compulsive disorder, bulimia, and 
schizoid personality disorder [28].
Regarding the VNTR polymorphism, 
there is strong evidence for increased fre-
quency of  allele 12 in subjects with bipo-
lar disorder [43,52]. Additionally, allele 9 
has been associated with unipolar disorder 
[53,54]. Finally, an increased frequency of  
the 10 allele together with the L allele of  the 
promoter polymorphism was observed in a 
suicide cohort [32]. Therefore, most of  the 
evidence suggests that this polymorphism is 
functional and may influence affective disor-
ders. On the other hand, no associations of  
affective disorders with the intronic VNTR 
were found in studies performed on Ger-
man, Japanese and Chinese populations [52]. 
As the association with depression has not 
always been reproducible there is a need to 
determine the exact association between the 
VNTR polymorphism and depressive pheno-
type [16]. 
Somatic illnesses were also investigated in 
regard to their association with the serotonin 
transporter polymorphism. Several studies 
showed a relationship between depression 
and the S allele, as a study by Gilbert and as-
sociates performed in a population of  head-
neck patients [55]. On the other hand, Phil-
lips-Bute and associates found that the LL, 
and not the SS genotype was associated with 
increased depressive symptoms one year after 
coronary artery bypass graft surgery, and that 
the presence of  the L allele was associated 
with increased incidence of  adverse cardiac 
events [56]. Grassi and associates found no 
association between 5-HTTLPR genotypes, 
serious life events and depression in breast 
cancer patients [57]. Therefore research on 
somatic illnesses is also characterized by in-
consistent findings.
Research among psychiatrically healthy 
individuals showed that individuals homozy-
gous for the S allele exhibit higher levels of  
depressivity and are more likely to have first-
degree relatives with a history of  depression 
[28]. Focusing more on depression, research 
about the association between 5-HTTLPR 
polymorphism and depression has produced 
inconsistent findings [58]. Several researches 
linked the functional polymorphism within 
the promoter region of  the 5-HTTLPR to 
major depressive disorder [59-62]. PET stud-
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ies also suggest widespread impairment of  
5-HT function, while postmortem studies 
report abnormal reductions of  brain 5-HT 
transporter sites in depression [47]. Further-
more, Cervilla and associates found that the 
SS genotype may play a small but indepen-
dent role in increasing the risk for major 
depression [63]. S allele of  the 5-HTTLPR 
has also been associated with increased risk 
of  developing major depression in patients 
with chronic psychotic disorders [64], as well 
as geriatric patients [65]. Moreover, S allele 
was found to be more frequent in depressed 
patients [43] and suicide victims [66], while 
others have not confirmed these findings 
[51,67]. Brown and associates reviewed a 
number of  studies and found no evidence for 
more than a small association of  5-HTTL-
PR with rates of  depression and concluded 
that the polymorphism has at best an effect 
of  modest size [68]. Newer studies focusing 
on the tri-allelic 5-HTTLPR polymorphism 
have established that the SS genotype of  the 
tri-allelic 5-HTTLPR polymorphism may be 
a risk factor that increases the susceptibility 
to major depression, at least in male Chinese 
population [69]. 
Several studies and reviews suggested 
the possibility that 5-HTTLPR may not be 
directly associated with depression or sui-
cide, but may rather modulate the seroto-
nergic response to life stress [70-73]. Indeed, 
most contemporary theories concerning the 
role of  genes in the onset of  depression are 
stress-diathesis theories. These theories are 
based on the fact that the S allele has been 
shown to interact with stressful life events 
(SLE) to predict depression with remarkable 
consistency [9-16]. Practically the only excep-
tions being studies by Surtees and Gillespie 
[74-75]. In addition, 5-HTTLPR may pre-
dispose to depression in patients with severe 
medical illnesses that are associated with on-
going chronic stress [76,77]. Therefore one 
might expect to find a direct effect of  the 
5-HTTLPR polymorphism on depression 
in groups of  chronically ill patients who are 
under considerable amounts of  stress. That 
was confirmed in several studies where the S 
allele has been associated with depression in 
patients with Parkinson’s disease, stroke, hip 
fracture and acute coronary syndrome [77]. 
Serotonin Transporter Polymorphism 
and its Association with Suicide
Special interest of  psychiatry was always 
directed towards the problem of  suicide. 
Therefore, it is of  no surprise that many 
studies examined the possible association 
between serotonin transporter, its polymor-
phisms and suicidal behavior. As a result, sev-
eral studies and meta-analyses [35,78] found 
evidence for a significant association of  the 
S allele and SS genotype with suicidal behav-
ior. However, research results have not been 
unanimous [79]. Similar was observed for the 
STin2 shorter 10 allele [2,79]. Furthermore, 
S allele of  the 5-HTTLPR polymorphism 
was associated particularly with violent sui-
cide attempts [33,78,80]. It was also shown 
that the S allele confers increased short term 
risk of  subsequent suicide attempts following 
a suicide attempt [47]. Joiner and associates 
reported that family history of  severe suicid-
ality was more common among participants 
with the SS genotype than among others [61]. 
Post-mortem study which showed a dif-
fuse reduction of  5-HT transporter binding 
in the prefrontal cortex of  individuals with 
depression who died of  suicide substanti-
ated the link between abnormalities in 5-HT 
transporter function, depression and suicidal 
behavior [50]. However, 5-HTTLPR poly-
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morphisms did not explain lower prefrontal 
cortex 5-HT transporter binding [47].
Although all findings mentioned above 
might suggest that a genetic alteration of  the 
serotonergic system could predispose people 
to psychiatric diseases and suicide, the exact 
effect and role of  5-HTTLPR in genetics of  
suicide is still unclear and should be inves-
tigated further in future studies [18]. That 
is especially the case because several studies 
have not confirmed the association between 
the S allele and suicidal behavior [18,47,81].
Serotonin Transporter Polymorphism 
and its Association with 
Antidepressants Use
Changes in serotonin transporter alter the 
expression and/or function of  most, if  not 
all, serotonin receptors as well as the synthe-
sis, clearance and metabolism of  serotonin. 
These changes have important clinical im-
plications for serotonin targeted psycho-
pharmacotherapy as they might interfere or 
negate the effects of  medication. These psy-
chopharmacs include serotonin reuptake in-
hibitors (SRI’s), selective serotonin reuptake 
inhibitors (SSRI’s) and combined serotonin-
norepinephrine reuptake inhibitors (SNRI’s).
When taking a closer look at the 5-HT-
TLPR polymorphism, it is unclear why the 
S allele carriers would be disadvantageous to 
metabolism of  serotonin. That is especially 
the case since reduced serotonin transporter 
function induced by SSRI’s and other sero-
tonin targeted antidepressants improves de-
pression and impulsiveness (two conditions 
frequently associated with suicidal behavior). 
However, majority of  studies and meta-anal-
yses that examined the association between 
the serotonin transporter polymorphism and 
therapeutic response to SSRI’s found the SS 
genotype and S allele associated with lower 
antidepressant efficacy, compared with pa-
tients with the LL genotype [82-89] although 
this has been disputed [90,91]. All of  the 
nowadays known SSRI antidepressants have 
been investigated in regard to their therapeu-
tic efficacy associated with 5-HTTLPR poly-
morphisms. Arias and associates reported a 
significant association between the S allele 
and no clinical remission after 3 months of  
treatment with citalopram [85,92]. Smeraldi 
and associates have shown that subjects with 
LL and LS genotype responded significant-
ly better to fluvoxamine than subjects with 
the SS genotype [93]. Patients with the LL 
genotype respond more favorably and faster 
to paroxetine [83,94]. Similarly, patients with 
the LL genotype respond faster to sertraline 
than those with the SS genotype [95]. Rausch 
and associates have reported an association 
between the LL genotype and improved re-
sponse to fluoxetine [96]. These studies sug-
gest a clinically significant effect of  increased 
baseline transcriptional activity and serotonin 
reuptake to SSRI response, due in part to 
polymorphic variation within the gene. How-
ever, these findings may apply primarily to 
Caucasian populations, as several studies re-
ported associations between the S allele and 
more favorable treatment outcomes in Asian 
populations [89,90,97].
Serotonin transporter polymorphism has 
not only been associated with therapeutic re-
sponses but also with various adverse events 
of  serotonergic psychopharmacs. Several 
studies found greater numbers and a greater 
variety of  side effects during SSRI treatment 
in S allele or SS genotype individuals [88,98-
101]. More specifically, Perlis and associates 
reported a 3.5-fold greater incidence of  in-
somnia and a 9.5-fold greater incidence of  
agitation during treatment with fluoxetine in 
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individuals with the SS genotype compared to 
SL or LL individuals [98]. Hu and associates 
found that the S allele and SS genotype were 
strongly associated with intolerance to cita-
lopram treatment [102]. In bipolar patients 
treated with serotonergic antidepressants, a 
5.3-fold higher incidence of  hypomania as 
a side effect occurred with the SS genotype 
compared to the other genotypes [103] and 
S allele carriers had higher rates of  switching 
from depression to mania [3]. 
One explanation about why humans with 
the SS genotype and mice with reduced sero-
tonin transporter have deficient responses to 
antidepressants is that a “plateau” effect may 
be responsible. That basically means that fur-
ther inhibition of  serotonin transporter ac-
tivity might not be meaningful or adequate 
[2].
Everything stated leads us to conclude 
that it is very important to determine individ-
ual’s genotype as it can influence therapeutic 
efficacy and adverse event profile of  SSRI’s 
and other serotonin targeted antidepressants.
Additional Factors Associated with 
Interaction of Depression and 
Serotonin System
Gene-environment Interactions - Serious Life 
Events
Connection between depression and the 
serotonin system has been examined and 
substantiated very often, but only recently 
research focused on the link between sero-
tonin and stress, as well as their combined in-
fluence on depression. Scientific research has 
identified several factors with at least some 
effect on the mentioned association of  sero-
tonin transporter polymorphism and depres-
sion, and those are: gene-environment inter-
actions (GxE), biological stress reactivity and 
personality traits, namely neuroticism.
Considering the multifactorial etiology 
of  affective disorders idea has emerged that 
environmental factors should be involved in 
the genetic assessments, the so called gene-
environment interactions or GxE. As al-
ready mentioned, majority of  studies in this 
area have investigated exposure to stressful 
life events (SLE) as environmental factors. 
Evidence for gene–environment interaction 
(GxE) involving the polymorphism in the 
promoter of  the serotonin transporter geno-
type (5-HTTLPR) and adult depression was 
first reported by Caspi and associates [34]. In 
this study S allele carriers showed more severe 
depressive symptoms and were at greater risk 
to develop depression compared with the LL 
genotype. In addition, Zalsman and associ-
ates found that the S allele predicted more 
lifetime depressive episodes [77]. Recent me-
ta-analysis however did not provide evidence 
of  clear association [104]. Research results on 
first onset of  depression found that S allele 
carriers were associated with the presence of  
SLE prior to onset of  depression [59]. Fur-
thermore, number of  studies confirmed the 
interaction between 5-HTTLPR and SLE in 
predicting onset of  depression [105-107], 
severity of  depressive symptoms [77] and 
suicidal ideation [108]. These findings were 
confirmed by Kendler and associates who re-
ported that individuals homozygous for the S 
allele are more sensitive to the depressogenic 
effect of  serious life events than L allele car-
riers [105]. Several studies confirmed these 
findings [106,109-111] including research on 
the role of  serotonin in animals [51], others 
not completely [70,112], whereas some have 
failed to establish any gene-environment in-
teraction [74,75,113-116] or even an effect in 
the opposite direction [117-119] compared 
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to the original findings by Caspi and asso-
ciates [34]. Kendler and associates also no-
ticed that the association between SLE and 
depression declines with increasing number 
of  depressive episodes. In light of  that find-
ing they theorized that this proposed change 
in reactivity to stressors across the course of  
repeated episodes may itself  be modified by 
genetic factors [120]. 
It is also important to note studies by 
Kaufman, Taylor and their associates which 
have established that a supportive environ-
ment may counteract SS predisposition to 
depression in abused children and even be 
beneficial to individuals with the SS genotype 
[110,121].
It has been hypothesized that these dis-
crepancies may be explained by the assump-
tion that other regions of  the SLC6A4 in-
teract with the functions mediated by the 
5-HTTLPR polymorphism. In accordance 
with that theory, Lazary and associates sug-
gested that in addition to the promoter re-
gion, the middle region, marked by the A 
allele of  rs140700, of  the SLC6A4 gene ex-
hibits a modifying effect on gene function 
[122].
In light of  all findings mentioned, Becker 
and associates suggested that the S allele of  
the 5-HTTLPR gene confirms a vulnerability 
to depression only in individuals with histo-
ries of  significant stress. In the absence of  
these experiences, the S allele appears to con-
tribute little to the development of  depres-
sion [15].
Biological Stress Reactivity
Biological stress reactivity may also turn 
out to be a very important mechanism under-
lying the association between the serotonin 
transporter gene and exposure to serious life 
events in increasing the risk for depression. 
That is especially the case if  we consider that 
serotonin system is involved in both activa-
tion and feedback control of  the HPA axis, 
therefore having a crucial role in regulation 
of  its activity, even though HPA axis and 
hormone cortisol are central elements of  
the biological stress reactivity theory [123]. 
In animals serotonin was found to activate 
the HPA axis by stimulating CRF [124]. Fur-
thermore, mice with knocked out serotonin 
transporter gene have increased HPA axis 
response to acute stress [125]. Barr and as-
sociates [126] found that in infant rhesus 
macaques serotonin transporter gene varia-
tion affects HPA axis activity. As mentioned 
earlier, S allele has generally been found to 
be associated with greater risk for depres-
sion than LL genotype. Gotlib and associates 
therefore theorized that a single laboratory 
stressor is too mild and transient to produce 
cortisol production in LL and SL individuals 
but sufficient to provoke a cortisol response 
in SS participants [127]. Therefore, individu-
als with the SS genotype may have a lower 
threshold for cortisol production in response 
to stress.
Consistent with the idea of  stress reac-
tivity, researchers have found cortisol to be 
elevated in 40%–60% of  adults with major 
depression [128]. Furthermore, some stud-
ies have provided information about the as-
sociation between the S allele and elevated 
cortisol levels. On that note, several studies 
established that individuals with the SS geno-
type were associated with increased cortisol 
awakening response, although that effect was 
mostly seen in females [129,130]. In response 
to physiological stress, individuals with the SS 
genotype have increased plasma cortisol re-
sponse compared with individuals with the L 
allele, but curiously this was also shown for 
115
Alcoholism and Psychiatry Research 2015;51:107-126SERT in Depression
women only [131]. All being said, hypercor-
tisolemia can lead to hippocampal neuronal 
loss, which is involved in the pathogenesis 
of  depression [132]. Therefore, Gotlib and 
associates hypothesized that depressed in-
dividuals, many of  whom are likely to carry 
the S allele [34], are characterized by hyper-
cortisolemia not only because they have been 
exposed to a greater number of  stressful life 
events than nondepressed controls [133] but 
also because they are biologically more reac-
tive to stressors [134]. 
The idea of  stress reactivity may explain 
both Caspi’s [34] finding of  an increased like-
lihood of  developing depression in response 
to stressful events among S carriers and 
Kendler’s [105] finding of  the importance of  
low-threat events in predicting the onset of  
depression [127].
Personality Trait Neuroticism
As already stated, the association between 
the lower expressing S allele of  5-HTTLPR 
and susceptibility to depression in response 
to stressful life events is rather controversial. 
This inconsistency might be caused by not 
taking into account cognitive stress-vulnera-
bility as a pivotal factor in predicting depres-
sion symptoms. Therefore, the interaction 
between 5-HTTLPR genotype and neuroti-
cism, personality trait related to anxiety, stress 
reactivity and depression, might be a more 
powerful additional predictor of  depression 
symptoms than gene and stressful life events 
interaction [135].
In a study published in 1996, Lesch and 
associates reported that individuals carrying 
the S allele displayed higher levels of  neuroti-
cism[8]. Contrary to that finding, more recent 
studies suggest no impact of  serotonin trans-
porter polymorphisms on neuroticism [136]. 
Only modest associations have been reported 
between the S allele and relatively increased 
trait negative affect [40,41,137,138]. Individ-
uals with the S allele were also found to ex-
perience negative emotions more unpleasant, 
more influential, and disruptive on personal 
goals, as well as feel less able to cope with 
these emotions [139]. That could, at least par-
tially, be explained by the hypothesis that S al-
lele carriers experience negative events differ-
ently than non-carriers, or recall those events 
differently. Finding of  less subjective coping 
ability in S allele carriers is consistent with the 
results of  Wilhelm and associates who found 
that the S allele of  the serotonin transport-
er gene is associated with the use of  fewer 
problem-solving strategies and less efficient 
coping with stressful situations [140].
The S allele has been associated with rel-
atively increased risk for depression in the 
context of  environmental adversity [51], a re-
lationship that may be mediated by increased 
neuroticism, therefore amplifying the individ-
ual’s vulnerability to the experience of  SLE 
[141]. Indeed, the presence of  the S allele of  
the 5-HTTLPR and the experience of  SLE is 
associated with a higher level of  neuroticism 
[51]. Also, Jacobs and associates established 
that the effect of  SLE on depression was no 
longer dependent on 5-HTTLPR after taking 
neuroticism into account [142]. 
Neuroticism itself  has also been associ-
ated with depression [143] and the risk of  
exposure to SLE [144,145]. Positive associa-
tions between the S allele and increased trait 
negative affect or risk for depression have not 
been consistently demonstrated across stud-
ies [74,75,146]. However, data from the field 
of  imaging genetics has provided relatively 
consistent evidence for a link between the S 
allele and relatively heightened amygdala ac-
tivation to emotional stimuli relative to neu-
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tral stimuli, a key neural process underlying 
the generation of  behavioral and physiologic 
arousal to environmental threat [127,141].
Newer analyses confirmed that the SS al-
lele genotype, stress experience and neuroti-
cism are independently associated with high-
er depression scores. In light of  that finding, 
Verschoor and associates established that SS 
genotypes exhibit vulnerability to depressive 
symptoms only when reporting high stress 
and high neuroticism scores. That indicates 
that not stress events per se, but rather a cog-
nitive stress-vulnerability like neuroticism, 
interacts more powerfully with 5-HTTLPR 
genotype in promoting depression symptoms 
[135]. 
Conclusion
Everything said leads us to conclude that 
molecular and neural mechanisms that un-
derlie the interplay of  genes, environmental 
adversity and personality traits that consti-
tute disease risk remain incompletely under-
stood. Inconsistent conclusions observed in 
scientific research have proven to be the only 
constant finding while analyzing the pos-
sible association of  serotonin transporter 
polymorphism and depression. Why that is 
the case is still to be determined but those 
inconsistencies may be in some cases due to 
genotype interaction with a variety of  oth-
er factors: gender, social background, eth-
nic differences, as well as already discussed 
gene-environment interactions and serious 
life events, biological stress reactivity and 
personality traits. Furthermore, many studies 
addressing this issue acknowledge limitations, 
which often include small sample sizes, rec-
ognized or suspected variability in the clinical 
phenotype, and coexisting disorders. Also, it 
is difficult to compare across studies due to 
heterogeneity of  the included samples.
As SLC6A4 genotyping is a relatively new 
field of  research there are still areas that have 
not been examined in detail, one of  those 
is the aforementioned tri-allelic 5-HTTLPR 
polymorphism. Future may indeed lead to 
more extensive genotyping of  SLC6A4, while 
taking into account all newly discovered vari-
ants within the gene and its regions. Factors 
like life stress and environmental factors that 
may contribute to increased vulnerability in 
susceptible individuals should also be more 
extensively addressed as they may prove be 
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Povezanost polimorfizama serotoninskog transportera s depresijom
Sežatak – Serotonin se smatra jednim od najvažnijih čimbenika u modernoj psihijatriji te je značajna količina 
istraživanja posvećena upravo tom neurotransmiteru. Serotoninski transporter i njegovi razni polimorfizmi 
se smatraju povezanima s raznim psihijatrijskim poremećajima, većinom depresijom i suicidom. U svjetlu te 
činjenice, ovaj pregledni članak će pokušati prikazati nove podatke vezane uz polimorfizme serotoninskog 
transportera i njihovoj povezanosti s depresijom. Pošto je primjetan stalni porast istraživanja vezan za ovo 
područje psihijatrije, a koje danas uključuje i razne druge čimbenike nego što je prethodno bio slučaj, bilo je 
potrebno pružiti kratak pregled tih čimbenika. Stoga se u ovom članku raspravlja o polimorfizmima serotonin-
skog transportera i njihovoj povezanosti s gensko-okolišnim čimbenicima, modelu biološke stres reaktivnosti 
te crtama osobnosti, a zatim i o njihovim zajedničkim djelovanjima na depresiju. Nevezano za veličinu sveu-
kupnog znanja i istraživanja o serotoninu, jedino konstantno saznanje pri analizi moguće veze polimorfizama 
serotoninskog transportera i depresije su oprečni zaključci. Stoga se može zaključiti da molekularni i neuralni 
mehanizmi koji se nalaze u podlozi međuodnosa gena, čimbenika okoline i crta osobnosti, a koji predstavljaju 
rizik za razvoj bolesti, ostaju nedovoljno dobro razjašnjeni. Zbog tih oprečnih zaključka potrebno je i dalje 
istraživati SLC6A4, kao i druge gene te provesti istraživanja na većem broju ispitanika. Čimbenici poput stresa 
i čimbenika okoline, koji mogu pridonijeti povećanoj ranjivosti osjetljivih osoba, se također moraju detaljnije 
istražiti, pošto bi mogli biti ključem pravovremenog liječenja i učinkovitih preventivnih strategija.
Ključne riječi: serotoninski transporter, polimorfizam serotoninskog transportera, depresija

